Top Analyst Reports for JPMorgan Chase, AbbVie & Abbott

Zacks2022-08-19

Thursday, August 18, 2022 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 12 major stocks, including JPMorgan ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2260354705?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/uHr4xxpgCJ3of0rSWfwrtA--~B/aD01ODc7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/uu/api/res/1.2/k1h7Nf7YKXEJVG0fEMqg6A--~B/aD01ODc7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/d9b3f7b5ae7f67e58a203af36b3a7698","is_english":true,"pubTime":"2022-08-19 01:24","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2260354705","market":"us","top_or_hot":-1,"title":"Top Analyst Reports for JPMorgan Chase, AbbVie & Abbott","media":"Zacks","content":"<div>\n<p>Thursday, August 18, 2022\nThe Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 12 major stocks, including JPMorgan ...</p>\n\n<a href=\"https://finance.yahoo.com/news/top-analyst-reports-jpmorgan-chase-172405177.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Top Analyst Reports for JPMorgan Chase, AbbVie & Abbott</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTop Analyst Reports for JPMorgan Chase, AbbVie & Abbott\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-08-19 01:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/top-analyst-reports-jpmorgan-chase-172405177.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Thursday, August 18, 2022\nThe Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 12 major stocks, including JPMorgan ...</p>\n\n<a href=\"https://finance.yahoo.com/news/top-analyst-reports-jpmorgan-chase-172405177.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4559","symbol_name":"巴菲特持仓","start_time":0,"source_url":"https://finance.yahoo.com/news/top-analyst-reports-jpmorgan-chase-172405177.html","article_id":"2260354705","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/uHr4xxpgCJ3of0rSWfwrtA--~B/aD01ODc7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/uu/api/res/1.2/k1h7Nf7YKXEJVG0fEMqg6A--~B/aD01ODc7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/d9b3f7b5ae7f67e58a203af36b3a7698"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2260354705","pubTimestamp":1660843445,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Thursday, August 18, 2022\nThe Zacks Research Daily presents the best research output of our analyst ","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4559":"巴菲特持仓","BK4534":"瑞士信贷持仓","CAT":"卡特彼勒","ABBV":"艾伯维公司","BK4139":"生物科技","BK4568":"美国抗疫概念","ABT":"雅培","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4504":"桥水持仓","BK4550":"红杉资本持仓","BK4581":"高盛持仓","BK4566":"资本集团","JPM":"摩根大通","BK4207":"综合性银行","LIN":"Linde PLC","BK4082":"医疗保健设备"},"translate_title":"摩根大通、AbbVie和Abbott的顶级分析师报告","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABBV":1,"ABT":1,"JPM":1,"CAT":0.9,"LIN":0.6},"content_text":"Thursday, August 18, 2022\nThe Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 12 major stocks, including JPMorgan Chase & Co. (JPM), AbbVie Inc. (ABBV) and Abbott Laboratories (ABT). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today. You can see all of today’s research reports here >>>\nJPMorgan Chase shares have declined -18.3% over the past year against the Zacks Banks - Major Regional industry’s decline of -8.8%. The company’s capital markets business and higher mortgage rates are likely to make fee income growth challenging due to the uncertain macroeconomic environment. Moreover, steadily rising operating expenses remain a key near-term headwind. Notably, given the possibility of an economic downturn and to meet higher capital requirements, the bank has suspended buybacks.\nHowever, higher interest rates and growth in loan demand are expected to result in a robust improvement in net interest income (NII). Opening new branches, strategic buyouts/investments and global expansion and digitization initiatives are likely to keep aiding the top line.\n(You can read the full research report on JPMorgan Chase here >>>)\nAbbVie shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+24.0% vs. +4.9%), reflecting the company's successful label expansion of its cancer drugs, Imbruvica and Venclexta. It has several new drugs in its portfolio, which have the potential to drive revenues once Humira loses U.S. exclusivity in 2023.  \nSkyrizi and Rinvoq are going strong, bolstered by approval in new indications. It has several early/mid-stage candidates that have blockbuster potential. Allergan’s acquisition has diversified AbbVie’s revenue base into new therapeutic areas, enhancing its long-term growth potential.\nHowever, there are concerns about long-term sales growth once Humira generics enter the U.S. market. Increasing competition from newer therapies is hurting Imbruvica’s sales.\n(You can read the full research report on AbbVie here >>>)\nAbbott shares have declined -11.7% over the past year against the Zacks Medical - Products industry’s decline of -44.5%. The company’s total worldwide Nutrition and Pediatric Nutrition sales continued to be hampered due to the negative repercussions of a voluntary recall of certain powder formulae produced at one of Abbott's U.S. plants. Decline in organic sales in the Neuromodulation and Vascular businesses in the second quarter also raise worries.\nOffsetting these negatives, Abbott continues to enjoy robust organic sales growth across core operating segments, barring Nutrition, as reflected in its latest quarterly release. The Diabetes Care business continued to benefit from the growing sales of sensor-based continuous glucose monitoring system, FreeStyle Libre. The Zacks analyst are particularly upbeat about the receipt of FDA clearance for the company’s FreeStyle Libre 3 system in May 2022\n(You can read the full research report on Abbott here >>>)\nOther noteworthy reports we are featuring today include Linde plc (LIN), Intuit Inc. (INTU), and Caterpillar Inc. (CAT).\nSheraz Mian Director of Research\nNote: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>\nToday's Must Read\nHigher Rates to Aid JPMorgan (JPM) Margins, Fee Income A Woe\nAbbVie's (ABBV) Skyrizi, Rinvoq Key to Long-Term Growth\nHigh Medical Device Sales Aid Abbott (ABT), Forex Woes Stay\nFeatured Reports\nLinde (LIN) Benefits from Advanced Gas Processing SolutionsThe Zacks Analyst believes Linde's state-of-the-art solutions related to gas processing is likely to support customer expansion and help reduce emissions. Yet, higher costs of sales are concerning.\nIntuit (INTU) Rides on Product Refresh, Higher SubscriptionsPer the Zacks analyst, Intuit is benefiting from frequent product refreshes, which help it to gain customers. Moreover, increase in subscriptions is driving stable revenue growth for the company.\nAmerica Movil (AMX) Benefits from Increasing Subscriber BasePer the Zacks analyst, America Movil's performance is gaining from increased broadband client base However, stiff competition and the firm's high leverage remain concerns.\nAcquisitions & Cost-Cutting Initiatives Aid MetLife (MET)Per the Zacks analyst, several acquisitions and partnerships bolster the capabilities and global presence of MetLife. Efforts to control costs are driving its margins.\nInfrastructure Investment & Clean Assets Aid PPL (PPL)Per the Zacks analyst, PPL Corporation's investment of $12 billion through 2026, will strengthen its infrastructure and assist it to efficiently serve customers, which will boost its profitability.\nRobust Digital Ordering Aid Domino's (DPZ), High Costs AilPer the Zacks analyst, a solid digital ordering system and higher global retail sales bode well for Domino's. However, staffing challenges, supply chain problems and inflationary pressures hurts.\nRevenue Rise Ups Trane Technologies (TT) Despite Low LiquidityThe Zacks analyst is positive about Trane Technologies' (TT) growth objectives, aiming to increase its revenue streams from parts, services, used equipment and rentals. Low current ratio is a bane.\nNew Upgrades\nCaterpillar (CAT) to Gain on Strong Demand in End MarketsPer the Zacks analyst, solid backlog, improving end-market demand and focus on making strategic investments in expanded offerings, services and digital initiatives will drive Caterpillar's results.\nCenovus (CVE) to Gain From Alberta Tucker Asset DivestmentThe Zacks Analyst is upbeat about Cenovus' divestment of the Tucker thermal asset in Alberta, which is likely to help reduce the debt burden and raise shareholder returns.\nStrength in the End Market to Drive Applied Industrial (AIT)Per the Zacks analyst, solid demand across the technology, metals, refining, chemicals and automation end markets are likely to drive Applied Industrial's top-line performance in the quarters ahead.\nNew Downgrades\nSoft Comps Performance to Hurt Children's Place (PLCE) SalesPer the Zacks analyst, persistent of soft comps performance may hurt Children's Place sales. The company expects a low-double-digit decline in comps in both the third quarter as well as fiscal year.\nWeakening Memory Chip Demand to Hurt Micron's (MU) SalesPer the Zacks Analyst, weakening consumer spending on personal computers and smartphones is expected to negatively impact demand for Micron's memory chips in the near term.\nNews Corporation's (NWSA) Subscription Unit Remains SoftPer Zacks analyst, News Corporation is seeing a soft Subscription Video Services segment for a while. Lower revenues from residential broadcast product and currency headwinds hurt the unit's revenues.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. \nClick to get this free report\n \n\nJPMorgan Chase & Co. (JPM) : Free Stock Analysis Report\n \n\nAbbott Laboratories (ABT) : Free Stock Analysis Report\n \n\nCaterpillar Inc. (CAT) : Free Stock Analysis Report\n \n\nIntuit Inc. (INTU) : Free Stock Analysis Report\n \n\nAbbVie Inc. (ABBV) : Free Stock Analysis Report\n \n\nLinde plc (LIN) : Free Stock Analysis Report\n \n\nTo read this article on Zacks.com click here.\n \n\nZacks Investment Research","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":2,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2260354705"}